Abstract Library

#3794 Impact of gender on treatment decisions and outcome in patients with neuroendocrine neoplasms

Introduction: Gender differences affect the treatment of several diseases in both male and female patients. However, the influence of gender on treatment decisions and outcome in neuroendocrine neoplasms (NENs) has scarcely been investigated.

Conference:

Presenting Author: Beck J

Authors: Beck J, Siebenhüner A, Wild D, Christ E, Refardt J,

Keywords: gender bias, registry, survival analysis,

#3213 Hyponatremia and hypernatremia have an opposing effect on overall survival in neuroendocrine tumor patients treated with peptide receptor radionuclide therapy

Introduction: Hypo- and hypernatremia are common electrolyte abnormalities in patients with malignancy and have been independently associated with worse survival outcomes. To date, there is no data on the influence of dysnatremia on patients with neuroendocrine tumors (NET).

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author:

Authors: Refardt J, Brabander T, Minczeles N, Feelders R, de Herder W,

Keywords: hyponatremia, hypernatremia, survival, PRRT,

#3000 Patients with Somatostatin Receptor Type 2-Negative Neuroendocrine Tumors Have Sustained Inferior Survival Rates in a Propensity Score-Matched Analysis

Introduction: Sufficient expression of somatostatin receptor type 2 (SST2) in neuroendocrine tumors (NETs) is crucial for treatment with unlabelled somatostatin analogues (SSAs), or peptide receptor radionuclide therapy (PRRT) using radio-labelled SSAs. Impaired prognosis has been described for SST2-negative NET patients, however studies comparing matched SST2-positive and -negative subjects are missing.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Refardt J

Authors: Refardt J, Zandee W, Brabander T, Feelders R, Franssen G,

Keywords: somatostatin receptor type 2, outcome, propensity score analysis, survival,

#2905 DNA Methyltransferase Inhibitor Hydralazine Induces Upregulation of Somatostatin Type 2 Receptors in Human Neuroendocrine Tumor Cells

Introduction: Epidrugs like DNA methyltransferase inhibitors (DNMTi) can increase somatostatin receptor type 2 (SST2) expression in neuroendocrine tumor (NET) cells in vitro and in vivo. This effect could be used for NET patients with low SST2 expression who are currently ineligible for somatostatin analogue (SSA) treatment. However, the DNMTi known to stimulate SST2 have either a high toxicity profile or are not yet approved.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Refardt J

Authors: Refardt J, Klomp I, van Koetsveld P, Dogan-Oruç F, de Herder W,

Keywords: somatostatin type 2 receptor, BON-1, GOT-1, upregulation, DNA methyltransferase inhibitor, histone deacetylase inhibitor, epigenetic,